Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • jimbotool jimbotool Jan 30, 2013 1:19 PM Flag

    Will Wall St read a New York Times article or a Seeking Alpo artesticle?

    For your antiSENSE education " Still, Dr. Cy Stein, a longtime antisense researcher, said it was too early to say that antisense had arrived. There have been false dawns in the field before.

    Antisense drugs work essentially by shooting the messenger. The recipe to make a protein is carried from a gene in the nucleus into the body of a cell by a single strand of RNA, called messenger RNA.

    Antisense drugs are small snippets of synthetic DNA or RNA that bind to that messenger RNA in a way that inactivates or destroys it.

    In theory, an antisense drug can be made to shut down any gene, providing a means to develop a virtually unlimited number of drugs. But in practice, it has been difficult to deliver the drugs into cells with sufficient potency and lack of toxicity. Companies have developed ways to chemically modify the drugs to help in that regard..........NYT 1/29/2013

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Look, Short stuff knows it too ! If Wall Street doesn't know the facts it's not the first time. I only wish the dangerous problems with antisense drug had been corrected by now but they haven't been corrected . I don't see how they will be but I expect the hype to continue. Let's hope for the future ! I expect (KNOW) the insiders are dropping their paper this very minute. SAD!

    • You're taking one person's view in a God like fashion, how about ten second opinions before you dogmatically post that? Wait and see to find out that Cy whatever isn't too informed and is not God-like. t

      Sentiment: Strong Buy

      • 1 Reply to jetmanbash
      • INTRODUCING

        Prof. Cy Stein, MD, PhD

        Prof. Dr. Cy Stein is Head of Medical Genitourinary Oncology and Professor of Medicine, Urology and Molecular Pharmacology at the Albert Einstein College of Medicine, New York. He also serves as an Attending Physician at the Montefiore Medical Center and is a Diplomate of nearly 20 years' standing of both the American Board of Internal Medicine and the American Board of Oncology.
        Professor Stein is an internationally recognized innovator in the development of drugs based on antisense and RNA interference. In his distinguished career in research and treatment of cancers he has been involved for the past 15 years with leading preclinical and clinical trials of nucleic acid therapies. He is an editorial board member of Clinical Cancer Research, Molecular Cancer Therapeutics, Bioconjugate Chemistry and Cancer Gene Therapy, as well as Co-Editor of the journal Oligonucleotides (formerly Antisense and Nucleic Acid Drug Development) and has published over 150 papers in the field. Dr. Stein holds numerous patents related to experimental therapeutics with antisense and nucleic acids, and he is a world leader in this research area. He is currently on the scientific advisory boards of several companies including Genta and Atugen. Prof. Stein was a co-developer of Genta Inc's Genasense antisense drug for BCL-2-dependent breast cancer.

        Prof Stein is a medical doctor and also has a PhD in chemistry. He is an oncologist and was trained at the New York Hospital/Cornell Medical Center and the National Institutes of Health. He was a professor at the College of Physicians and Surgeons at Columbia University for 13 years prior to taking up the chair at the Albert Einstein College. He is a pioneer in the research on anti-sense therapies against HIV/AIDS.

 
ISIS
59.66+1.42(+2.44%)May 4 4:00 PMEDT